• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA's Breakthrough Designation is Working, Says Report

Article

Pharmaceutical Executive

April 21, 2016.

The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .

Read Jill Wechsler's view in Applied Clinical Trials.

Recent Videos